1Matsuo K, Ho H, Yatabe Y, et al. Risk factor differ for non- small-cell lung cancer with and without EGFR mutation: assessment of smoking and by a case-control study in Japanese [J]. Cancer Sci, 2010, 98(1):96-101.
2Bell D W, Lynch T J, Haserlat S M, et al. Epidermal growth factor receptor mutations and gene amplification in lion small- cell lung caner:mohedar analysis of the 1DEAL/INTACT gefitinib mals [J]. J Clin Oncol, 2010, 23(31):8081-8092.
3Kishore U, Greenhough T J, Waters P, et al. Surfactant proteins SP-A and SP-D: structure, function, and receptors [J]. Mol Immunol, 2009, 43( 1 ) : 1293-1315.
4Yamaguchi H, Soda H, Nakamura Y, et al. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer [J]. Cancer Chemother Pharmacol, 2010, 4(1) :41-47.
5Italiano A, Cortot A B, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy [J]. Int J Cancer, 2010, 125(10):2479-2482.
6Eberhard D A, Johnson B E, Amler L C, et al. Mutations in the epidermal growth factor receptor and in KRAS arepredictive and prognostic indicators in patients with non-small- cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J]. J Clin Oncol, 2010, 23(25): 5900-5909.
7Wang S, An T, Wang J, et al. Potential clinical significance of a plasma-based kras mutation analysis in patients with advanced non-small cell lung cancer [J]. Clin Cancer Res, 2010, 16(4) : 1324-1330.
8Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inbibitors in non-small cell lung cancer [Jl. Clin Cancer Res, 2009, 13 (10) :2890- 2896.
9Kwak E L, Sordella R, Bell D W, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [J]. Proc Natl Acad Sci, 2010, 102(2) :7665-7670.
10Hirsch F R, Varella-Garcia M, Bunn Jr P A, et al. Molecular predictors of outcome with gefitinib in phase llI placebo- controlled study in advanced non-small-cell lung cancer [J]. J Clin Oncol, 2010, 24(3):5034-5042.
同被引文献27
1Simon GR,Turrisi A.American College of Chest Physicians,Management of small cell lung cancer:ACCP evidence-based clinical practice guidelines(2nd edition)[J].Chest,2007,132(3 Suppl):324S-339S
3GERBER D E,SCHILLER J H.Maintenance chemotherapy for advanced non-small-cell lung cancer:new life for an old idea[J].J Clin Oncol,2013,31(8):1009-1020.
4YANC L,REN B,LI H,et al.Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients[J].Cancer Immunol Immunother,2013,62(1):65-73.
